Market Closed -
Nasdaq
02:00:00 04/05/2024 am IST
|
5-day change
|
1st Jan Change
|
6.15
USD
|
+12.02%
|
|
+11.82%
|
+43.69%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
119.7
|
89.28
|
65.58
|
46.52
|
66.17
|
-
|
-
|
Enterprise Value (EV)
1 |
119.7
|
89.28
|
65.58
|
46.52
|
66.17
|
66.17
|
66.17
|
P/E ratio
|
-14.1
x
|
-7.06
x
|
-4.61
x
|
-2.91
x
|
-3.02
x
|
-3.27
x
|
-4.07
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
17
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
-
|
-
|
17
x
|
EV / EBITDA
|
-
|
-70,94,197
x
|
-49,54,807
x
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-84,16,928
x
|
-51,25,032
x
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-0%
|
-0%
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
6,218
|
11,188
|
10,857
|
10,869
|
10,759
|
-
|
-
|
Reference price
2 |
19.25
|
7.980
|
6.040
|
4.280
|
6.150
|
6.150
|
6.150
|
Announcement Date
|
10/03/21
|
10/03/22
|
20/03/23
|
18/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
3.9
|
EBITDA
|
-
|
-12.58
|
-13.23
|
-
|
-
|
-
|
-
|
EBIT
1 |
-5.908
|
-12.59
|
-14.43
|
-17.88
|
-24.8
|
-30.01
|
-35.8
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-917.95%
|
Earnings before Tax (EBT)
1 |
-5.908
|
-12.36
|
-14.26
|
-15.96
|
-23.3
|
-27.66
|
-33.1
|
Net income
1 |
-5.908
|
-12.36
|
-14.26
|
-15.96
|
-23.03
|
-28.47
|
-33.1
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-848.72%
|
EPS
2 |
-1.370
|
-1.130
|
-1.310
|
-1.470
|
-2.033
|
-1.883
|
-1.510
|
Free Cash Flow
|
-
|
-10.61
|
-12.8
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
10/03/21
|
10/03/22
|
20/03/23
|
18/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-4.147
|
-3.509
|
-4.064
|
-
|
-1.841
|
-3.493
|
-3.949
|
-4.794
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-4.149
|
-3.511
|
-4.066
|
-4.395
|
-2.145
|
-3.826
|
-4.286
|
-5.19
|
-3.524
|
-4.877
|
-5.4
|
-5.9
|
-6.5
|
-7.1
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-4.054
|
-3.54
|
-4.122
|
-4.492
|
-2.265
|
-3.381
|
-3.868
|
-4.746
|
-3.161
|
-4.186
|
-4.7
|
-5.3
|
-5.9
|
-6.6
|
Net income
1 |
-4.054
|
-3.54
|
-4.122
|
-4.492
|
-2.265
|
-3.381
|
-3.868
|
-4.746
|
-3.161
|
-4.186
|
-4.7
|
-5.3
|
-5.9
|
-6.6
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.3600
|
-0.3100
|
-0.3800
|
-0.4100
|
-0.2100
|
-0.3100
|
-0.3600
|
-0.4400
|
-0.2900
|
-0.3800
|
-0.4300
|
-0.4800
|
-0.5400
|
-0.6000
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
01/11/21
|
10/03/22
|
03/05/22
|
08/08/22
|
07/11/22
|
20/03/23
|
09/05/23
|
09/08/23
|
08/11/23
|
18/03/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-10.6
|
-12.8
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
-
|
0.03
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
10/03/21
|
10/03/22
|
20/03/23
|
18/03/24
|
-
|
-
|
-
|
Last Close Price
6.15
USD Average target price
22
USD Spread / Average Target +257.72% Consensus |
1st Jan change
|
Capi.
|
---|
| +43.69% | 66.17M | | +25.69% | 47.86B | | +46.90% | 41.42B | | -3.46% | 40.66B | | -6.20% | 28.92B | | +9.17% | 25.55B | | -20.42% | 19.27B | | +0.17% | 12.15B | | +28.07% | 12.14B | | -1.24% | 11.99B |
Other Biotechnology & Medical Research
|